REFERENCES

- **Abraham, TP, Nishimura, RA.(2001):**
  Myocardial strain: can we finally measure contractility?.
  J Am Coll Cardiol; 37:731.

- **Ajijola, OA, Nandigam, KV, Chabner, BA, et al.(2008):** Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy.
  Am J Cardiol; 101:1371.

- **Alexander, J, Dainiak, N, Berger, HJ, et al.(1979):**
  Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiography.
  N Engl J Med; 300:278.

- **Armenian, SH, Sun, CL, Francisco, L, et al.(2008):**
  Late congestive heart failure after hematopoietic cell transplantation.
  J Clin Oncol; 26:5537.

- **Auner, HW, Tinchon, C, Linkesch, W, et al.(2003):**

Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies.
Ann Hematol; 82:218.

- **Bacchieri A, Della Cioppa G. (2007):**
  Using and understanding medical statistics.
  Journal of Clinical Pharmacology; 47(8):1059-1060.

- **Barry E, Alvarez JA, Scully RE, et al. (2007) :**

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
. *Expert Opin Pharmacother 8:1039–1058.*

- **Barry, EV, Vrooman, LM, Dahlberg, SE, et al.(2008):**

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
J Clin Oncol; 26:1106.

- **Basilico, FC, Folland, ED, Karaffa, S, et al.(1981):**
Non-invasive measurement of left ventricular function in coronary artery disease. Comparison of first pass radionuclide ventriculography, M-mode echocardiography, and systolic time intervals.
Br Heart J; 45:369.

- **Bates, SE, Rosing, DR, Fojo, T, Piekarz, RL.(2006):**
Challenges of evaluating the cardiac effects of anticancer agents.
Clin Cancer Res; 12:3871.

- **Bavelaar-Croon, CD, Pauwels, EK, van Der, Wall EE.(2001):**
Gated single-photon emission computed tomographic myocardial imaging: A new tool in clinical cardiology.
Am Heart J; 141:383.

- **Bellenger, NG, Burgess, MI, Ray, SG, et al.(2000):**
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?.
Eur Heart J; 21:1387.

- **Bird BR, Swain SM. (2008) :**
Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
Clin Cancer Res 14:14–24.

- **Bryant, J, Picot, J, Baxter, L, et al.(2007):**
Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review.
Eur J Cancer; 43:1959.

- **Burow, RD, Strauss, HW, Singleton, R, et al.(1977):**
Analysis of left ventricular function from multiple gated acquisition cardiac blood pool imaging. Comparison to contrast angiography. *Circulation; 56:1024*.

- **Cardinale D, Colombo A, Sandri MT, et al. (2006) :**
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Circulation 114:2474–2481.

- **Cardinale D, Sandri MT, Colombo A et al.(2004):**
Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.
Circulation;109:2749–2754.

- **Cardinale D, Sandri MT, Martinoni A, et al. (2002) :**
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy.
Ann Oncol 13:710–715.

- **Cardinale D, Sandri MT, Martinoni A, et al. (2000) :**
Left ventricular dysfunction by early troponin I release after high-dose chemotherapy.
J Am Coll Cardiol 36:517–522.

- **Casper, ES, Gaynor, JJ, Hajdu, SI, et al.(1991):**
A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. *Cancer; 68:1221*.

- **Cerqueira, MD.(2002):**
Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.
Circulation; 105:539.

- **Cheitlin, MD, Armstrong, WF, Aurigemma, GP, et al.(1997):**
ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the Guidelines for the Clinical Application of Echocardiography).
Circulation 2003; 108:1146.

- **Chu TF, Rupnick MA, Kerkela R, et al. (2007) :**
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
Lancet 370:2011–2019.

- **Constantinesco, A, Mertz, L, Brunot, B.(1997):**
Myocardial perfusion and function imaging at rest with simultaneous thallium-201 and technetium-99m blood-pool dual-isotope gated SPECT.
J Nucl Med; 38:432.

- **Cooper, LT, Baughman, KL, Feldman, AM, et al.(2007):**
The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.
Circulation; 116:2216.

- **Corsi, C, Lang, RM, Veronesi, F, et al.(2005):**
Volumetric quantification of global and regional left ventricular function from real-time three-dimensional echocardiographic images.
Circulation; 112:1161.

- **Dalen, E, Caron, H, Dickinson, H, Kremer, L.(2005):**
Cardioprotective interventions for cancer patients receiving anthracyclines.
Cochrane Database Syst Rev; :CD003917.

- **Danias, PG, Ahlberg, AW, Clark, BA 3rd, et al.(1998):**
Combined assessment of myocardial perfusion and left ventricular function with exercise technetium-99m sestamibi gated single-photon emission computed tomography can differentiate between ischemic and nonischemic dilated cardiomyopathy.
Am J Cardiol; 82:1253.

- **Danias, PG, Papaioannou, GI, Ahlberg, AW, et al.(2004):**
Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy.
Am J Cardiol; 94:14.

- **Daniel, GK, Chawla, MK, Sawada, SG, et al.(2001):**
Echocardiographic imaging of technically difficult patients in the intensive care unit: use of optison in combination with fundamental and harmonic imaging.
J Am Soc Echocardiogr; 14:917.

- **DePuey, EG, Nichols, K, Dobrinsky, C.(1993):**
Left ventricular ejection fraction assessed from gated technetium-99m-sestamibi SPECT.
J Nucl Med; 34:1871

- **Dodos F, Halbsguth T, Erdmann E, Hoppe UC. (2008) :**
Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Clin Res Cardiol 97:318–326.

- **Doroshow JH.(1983)**:
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Cancer Res;43:460-472.

- **Douraid k, Kakil I Rasul.(2009):**
Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management.
J clin Med;19:129.

- **Dresdale A, Bonow RO, Wesley R, Palmeri ST, Barr L, Mathison D, D'Angelo T, et al.(1983):**

Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas.
Cancer;52:51-60.

- **Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E. (1986):**

Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice.
Cancer Res;46:54-60.

- **Elliott P. (2006) :**

Pathogenesis of cardiotoxicity induced by anthracyclines.
Semin Oncol 33:S2–S7.

- **Ewer MS, Martin FJ, Henderson IC, et al. (2004) :**

Cardiac safety of liposomal anthracyclines.
Semin Oncol 31(Suppl 13):161–181.

- **Ewer MS, O'Shaughnessy JA. (2007):**

Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Clin Breast Cancer 7:600–607.

- **Ewer MS, Lenihan DJ. (2008a) :**

cardiotoxicity: is our ear really to the ground?
J Clin Oncol 26:1–3.

- **Ewer, MS, Lenihan, DJ.((2008 b):**

Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?.
J Clin Oncol; 26:1201

- **Floyd JD, Nguyen DT, Lobins RL, et al. (2005)** :

Cardiotoxicity of cancer therapy.
J Clin Oncol 23:7685–7696.

- **Folland, ED, Parisi, AF, Moynihan, PF, et al.(1979):**
Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques.
Circulation; 60:760.

- **Frishman WH, Sung HM, Yee HC, Liu LL, Keefe D, Einzig AI, Dutcher J.(1997):**
Cardiovascular toxicity with cancer chemotherapy.
Curr Probl Cancer;21:301-360.

- **Fuster V, Gersh BJ, Giuliani ER et al.(1981):**
The natural history of idiopathic dilated cardiomyopathy.
Am J Cardiol;47:525–531.

- **Gennari A, Salvadori B, Donati S, et al. (1999) :**
Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.
J Clin Oncol 17:3596–3602.

- **Germanakis, I, Anagnostatou, N, Kalmanti, M.(2008):**
Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity.
Pediatr Blood Cancer; 51:327.

- **Germanakis, I, Kalmanti, M, Parthenakis, F, et al.(2006):**
Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
Int J Cardiol; 108:212.

- **Gopal, AS, Shen, Z, Sapin, PM, et al.(1995):**
Assessment of cardiac function by three-dimensional echocardiography compared with conventional noninvasive methods.
Circulation; 92:842.

- **Hamada, H, Ohkubo, T, Maeda, M, Ogawa, S.(2006):**
Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer.
Pediatr Int; 48:313.

- **Hambye, AS, Dobbeleir, A, Vervaet, A, Chi-Chou, H.(1997):**
Can we rely on 99Tcm-sestamibi gated tomographic myocardial perfusion imaging to quantify left ventricular function? A comparative study with classical isotopic techniques for the measurement of ejection fraction.
Nucl Med Commun; 18:751.

- **Haq, MM, Legha, SS, Choksi, J, et al.(1985):**
Doxorubicin-induced congestive heart failure in adults.
Cancer; 56:1361.

- **Hegge, FN, Hamilton, GW, Larson, SM, et al.(1978):**
Cardiac chamber imaging: a comparison of red blood cells labeled with Tc-99m in vitro and in vivo.
J Nucl Med; 19:129.

- **Hensley, ML, Hagerty, KL, Kewalramani, T, et al.(2009):**
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
J Clin Oncol; 27:127.

- **Hequet O, Le QH, Moullet I, et al. (2004) :**
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
J Clin Oncol 22:1864–1871.

- **Herman, EH, Zhang, J, Lipshultz, SE, et al.(1999):**
Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.
J Clin Oncol; 17:2237.

- **Hershman, DL, McBride, RB, Eisenberger, A, et al.(2008):**
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
J Clin Oncol; 26:3159.

- **Hudson, MM, Rai, SN, Nunez, C, et al.(2007):**
Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors.
J Clin Oncol; 25:3635.

- **Ioannidis, JP, Trikalinos, TA, Danias, PG.(2002):**
Electrocardiogram-gated single-photon emission computed tomography versus cardiac magnetic resonance imaging for the assessment of left ventricular volumes and ejection fraction: a meta-analysis.
J Am Coll Cardiol; 39:2059.

- **Iskandrian, AS, Heo, J, Kong, B, et al.(2004):**
Use of technetium-99m isonitrile (RP-30A) in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease, and comparison with coronary arteriography and exercise thallium-201 SPECT imaging.
Am J Cardiol; 64:270.

- **Isner, JM, Ferrans, VJ, Cohen, SR, et al.(1983):**
Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy.
Am J Cardiol; 51:1167.

- **Jannazzo A, Hoffman J, Lutz M. (2008) :**
Monitoring of anthracycline-induced cardiotoxicity.
Ann Pharmacother 42:99–104.

- **Jenkins, C, Bricknell, K, Hanekom, L, Marwick, TH.(2004):**
Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography.
J Am Coll Cardiol; 44:878.

- **Jensen BV, Skovsgaard T, Nielsen SL.((2002)):**
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
Ann Oncol 13:699–709.

- **Johnson, SH, Bigelow, C, Lee, KL, et al.(1991):**
The exercise ejection fraction predicts survival in coronary heart disease.
Am J Cardiol; 67:919.

- **Jones RL, Ewer MS. (2006a) :**
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
Expert Rev Anticancer Ther 6:1249–1269.

- **Jones RL, Swanton C, Ewer MS.(2006b):**
Anthracycline cardiotoxicity.
Expert Opin Drug Saf 5:791–809.

- **Jones LW, Haykowsky MJ, Swartz JJ, et al. (2007) :**
Early breast cancer: therapy and cardiovascular injury.
J Am Coll Cardiol 50:1435–1441.

- **Kalay, N, Basar, E, Ozdogru, I, et al.(2006):**
Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
J Am Coll Cardiol; 48:2258.

- **Kang, YG, Chen, Y, Yu, M, et al.(1997):**
Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin toxicity.
J Clin Invest; 100:1501.

- **Kilickap S, Barista I, Akgul E et al.(2005):**
cTnT can be a useful marker for early detection of anthracycline cardiotoxicity.
Ann Oncol;16:798– 801.

- **Kircher BJ, Himelman RB, Schiller NB.(1990):**

Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava.
Am J Cardiol 15;66(4):493-6.

- **Koch, K, Oellig, F, Oberholzer, K, et al.(2005):**

Assessment of right ventricular function by 16-detector-row CT: comparison with magnetic resonance imaging.
Eur Radiol; 15:312.

- **Kremer, LC, Caron, HN.(2004):**

Anthracycline cardiotoxicity in children. N Engl.
J Med; 351:120.

- **Kuhl, HP, Schreckenberg, M, Rulands, D, et al.(2004):**

High-resolution transthoracic real-time three-dimensional echocardiography: quantitation of cardiac volumes and function using semi-automatic border detection and comparison with cardiac magnetic resonance imaging.
J Am Coll Cardiol; 43:2083.

- **Kuikka, JT, Britton, KE, Chengazi, VU, Savolainen, S.(1998):**

Future developments in nuclear medicine instrumentation: A review. *Nucl Med Commun; 19:3.*

- **Kuittinen, T, Husso-Saastamoinen, M, Sipola, P, et al.(2005):**

Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.
Bone Marrow Transplant; 36:1077.

- **Lacy, JL, Verani, MS, Ball, ME, et al.(1998):**

First-pass radionuclide angiography using a multiwire gamma camera and tantalum-178
.J Nucl Med; 29:1305.

- **Lang, RM, Bierig, M, Devereux, RB, et al.(2005):**
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.
J Am Soc Echocardiogr; 18:1440.

- **Lawson, MA, Blackwell, GG, Davis, ND, et al.(1996):**
Accuracy of biplane long-axis left ventricular volume determined by cine magnetic resonance imaging in patients with regional and global dysfunction.
Am J Cardiol; 77:1098.

- **Lee, BH, Goodenday, LS, Muswick, GJ, et al.(1987):**
Alterations in left ventricular diastolic function with doxorubicin therapy.
J Am Coll Cardiol; 9:184.

- **Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA.(1973):**
A clinicopathologic analysis of Adriamycin cardiotoxicity. *Cancer;32:302-314.*

- **Lefrak, EA, Pitha, J, Rosenheim, S, Gottlieb, JA.(1993):**
A clinicopathologic analysis of adriamycin cardiotoxicity.
Cancer; 32:302.

- **Lenihan, DJ, Esteva, FJ.(2008):**
Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.
Oncologist; 13:1224.

- **Lipshultz, SE, Rifai, N, Sallan, SE, et al.(1997):**
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.
Circulation; 96:2641.

- **Lipshultz, SE, Giantris, AL, Lipsitz, SR, et al. (2002a):**
Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
J Clin Oncol; 20:1677.

- **Lipshultz, SE, Lipsitz, SR, Sallan, SE, et al. (2002b):**
Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer.
J Clin Oncol; 20:4517.

- **Lipshultz, SE, Colan, SD.(2004):**
Cardiovascular trials in long-term survivors of childhood cancer.
J Clin Oncol; 22:769.

- **Lipshultz, SE, Lipsitz, SR, Sallan, SE, et al.(2005):**
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
J Clin Oncol; 23:2629.

- **Mahnken, AH, Hohl, C, Suess, C, et al.(2006):**
Influence of heart rate and temporal resolution on left-ventricular volumes in cardiac multislice spiral computed tomography: a phantom study.
Invest Radiol; 41:429.

- **Marwick, TH.(2006):**
Measurement of strain and strain rate by echocardiography: ready for prime time?.
J Am Coll Cardiol; 47:1313.

- **Mavinkurve-Groothuis, AM, Kapusta, L, Nir, A, Groot-Loonen, J. (2008):**
The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.
Pediatr Hematol Oncol; 25:655.

- **Meinardi MT, van der Graaf WTA, Gietema JA, et al. (2002) :**

Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
Heart 88:81–82.

- **Mele, D, Campana, M, Sclavo, M, et al.(2003):**

Impact of tissue harmonic imaging in patients with distorted left ventricles: improvement in accuracy and reproducibility of visual, manual and automated echocardiographic assessment of left ventricular ejection fraction.
Eur J Echocardiogr; 4:59.

- **Mercuro G, Cadeddu C, Piras A, et al. (2007):**

Early epirubicin-induced myocardial dysfunction revealed by serial tissue doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Oncologist 12:1124–1133.

- **Minotti, G, Mancuso, C, Frustaci, A, et al.(1996):**

Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity.

- **Minow RA, Benjamin RS, Lee ET, Gottlieb JA.(1977):**

Adriamycin cardiomyopathy—risk factors.
J Clin Invest; 98:650.

- **Moghrabi, A, Levy, DE, Asselin, B, et al.(2007):**

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
Blood; 109:896.

- **Mohiuddin, IH, Kambara, H, Ohkusa, T, et al.(1992):**

Clinical evaluation of cardiac function by ambulatory ventricular scintigraphic monitoring (VEST): Validation and study of the effects of nitroglycerin and nifedipine in patients with and without coronary artery disease.
Am Heart J; 123:386.

- **Moriel, M, Rozanski, A, Klein, J, et al.(1997):**
The differing prognostic utility of exercise radionuclide ventriculography in coronary artery disease patients with and without prior myocardial infarction.
Int J Card Imaging; 13:403.

- **Mortelmans, L, Vanhecke, W, Mertens, D, et al.(2001):**
Assessment of the optimal atrioventricular delay in dual chamber-paced patients by a portable scintillation probe (VEST).
J Nucl Cardiol; 3:321.

- **Nagueh Sherif F, Chair C F, Christopher P. A et al.(2009**):
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography.
European Journal of = Echocardiography; 10(2):165-193.

- **Nakamae, H, Tsumura, K, Terada, Y, et al.(2005):**
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Cancer; 104:2492.

- **Nichols, K, DePuey, EG, Rozanski, A, et al.(1997):**
Image enhancement of severely hypoperfused myocardia for computation of tomographic ejection fraction.
J Nucl Med; 38:1411.

- **Nousiainen T, Jantunen E, Vanninen E et al.(1999):**
Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma.
Eur J Haematol;62:135–141.

- **Nousiainen T, Vanninen E, Jantunen E et al.(2002):**
Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.
J Intern Med;251:228–234.

- **Nousiainen, T, Jantunen, E, Vanninen, E, Hartikainen, J. (2002):**
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Br J Cancer; 86:1697.

- **O'Shaughnessy J, Twelves C, Aapro M. (2002) :**
Treatment for anthracycline-pretreated metastatic breast cancer. *Oncologist 7(Suppl 6):4–12.*

- **Pacher, P, Liaudet, L, Bai, P, et al.(2003):**
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. *Circulation; 107:896.*

- **Palmeri, ST, Bonow, RO, Myers, CE, et al.(1986):**
Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
Am J Cardiol; 58:607.

- **Pancholy, SB, Fattah, AA, Kamal, AM, et al.(1995):**
Independent and incremental prognostic value of exercise thallium single-photon emission computed tomographic imaging in women.
J Nucl Cardiol; 2:110.

- **Pein, F, Sakiroglu, O, Dahan, M, et al.(2004):**
Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy.
Br J Cancer; 91:37.

- **Perez EA, Suman VJ, Davidson NE, et al. (2004):**
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
J Clin Oncol 22:3700–3704.

- **Pini, R, Giannazzo, G, Di Bari, M, et al.(1997):**
Transthoracic three-dimensional echocardiographic reconstruction of left and right ventricles: In vitro validation and comparison with magnetic resonance imaging.
Am Heart. J; 133:221.

- **Posner, LE, Dukart, G, Goldberg, J, et al.(1985):**
Mitoxantrone: an overview of safety and toxicity.
Invest New Drugs; 3:123.

- **Raman, SV, Shah, M, McCarthy, B, et al.(2006):**
Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance.
Am Heart .J; 151:736.

- **Ryberg M, Nielsen D, Skovsgaard T, et al. (1998) :**
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
J Clin Oncol 16:3502–3508.

- **Ryberg, M, Nielsen, D, Cortese, G, et al.(2008):**
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
J Natl Cancer Inst; 100:1058.

- **Saletan, S.(1987):**
Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.
Cancer Treat Rev; 14:297.

- **Schiller, NB, Shah, PM, Crawford, M, et al.(1998):**
Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.
J Am Soc Echocardiogr; 2:358.

- **Schuchter, LM, Hensley, ML, Meropol, NJ, et al.(2002):**
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology.
J Clin Oncol; 20:2895.

- **Schwartz, RG, McKenzie, WB, Alexander, J, et al.(1987):**
Congestive heart failure and left ventricular dysfunction complication doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
Am J Med; 82:1109.

- **Seifert, CF, Nesser, ME, Thompson, DF.(1994):**
Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. *Ann Pharmacother; 28:1063.*

- **Shakir k, (2009)**
Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management
J clin Med;19:129.

- **Shankar, SM, Marina, N, Hudson, MM, et al.(2008):**
Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the Children's Oncology Group.
Pediatrics; 121:e387.

- **Shapira, J, Gotfried, M, Lishner, M, Ravid, M.(1990):**
Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation.
Cancer; 65:870.

- **Shapiro, CL, Hardenbergh, PH, Gelman, R, et al.(1998):**
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.
J Clin Oncol; 16:3493.

- **Shaw, LJ, Heinle, SK, Borges-Neto, S, et al.(1998):**
Prognosis by measurements of left ventricular function during exercise. Duke Noninvasive Research Working Group.
J Nucl Med; 39:140.

- **Silber JH, Cnaan A, Clark BJ, et al. (2004) :**
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines.
J Clin Oncol 22:820–828.

- **Singal, PK, Iliskovic, N.(1998):**
Doxorubicin-induced cardiomyopathy.
N Engl J Med; 339:900.

- **Specchia, G, Buquicchio, C, Pansini, N, et al.(2005):**
Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines.
J Lab Clin Med; 145:212.

- **Speyer, JL, Green, MD, Zeleniuch-Jacquotte, A, et al.(1992):**
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
J Clin Oncol; 10:117.

- **Steinherz, LJ, Graham, T, Hurwitz, R, et al,(1992):**
Guidelines for monitoring anthracycline cardiotoxicity in children.
Pediatrics 1992; 89:942.

- **Sugeng, L, Mor-Avi, V, Weinert, L, et al.(2006):**
Quantitative assessment of left ventricular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomography with magnetic resonance reference.
Circulation; 114:654.

- **Swain SM, Whaley FS, Ewer MS. (2003) :**
Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
Cancer 97:2869–2879.

- **Taillefer, R, et al.(1997):**

Comparative diagnostic accuracy of T1-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women .

J Am Coll Cardiol; 29:69.

- **Tebbi, CK, London, WB, Friedman, D, et al.(2007):**

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.

J Clin Oncol; 25:493.

- **Thomas JD and Popovic ZB (2006):**

Assessment of ventricular function by cardiac ultrasound. The clinical impact of echocardiography and its future directions.

Am J Coll Cardiol 4:2012-2025.

- **Tjeerdsma, G, Meinardi, MT, van der Graaf, WTA, et al.(1999):**

Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: Autonomic versus echocardiographic variables.

Heart; 81:419.

- **Vainio, P, Jurvelin, J, Kuikka, J, et al.(1992):**

Analysis of left ventricular function from gated first-pass and multiple gated equilibrium acquisitions.

Int J Card Imaging; 8:243.

- **van Dalen, EC, Michiels, EM, Caron, HN, Kremer, LC. (2006a):**

Different anthracycline derivates for reducing cardiotoxicity in cancer patients.

Cochrane Database Syst Rev; :CD005006.

- **van Dalen, EC, van der, Pal HJ, Caron, HN, Kremer, LC. (2006b):**

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.

Cochrane Database Syst Rev; :CD005008.

- **van Dalen, EC, van der, Pal HJ, Kok, WE, et al. (2006c):**
Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
Eur J Cancer; 42:3191.

- **Vemmer, T, Steinbuchel, C, Bertram, J, et al.(2005):**
Cardiac phase-synchronized myocardial thallium-201 single-photon emission tomography using list mode data acquisition and iterative tomographic reconstruction.
Eur J Nucl Med; 24:276.

- **Vogelsang, TW, Jensen, RJ, Hesse, B, Kjaer, A.(2008)**:
BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity.
Int J Cardiol; 124:193.

- **Von Hoff, DD, Layard, MW, Basa, P, et al.(1979):**
Risk factors for doxorubicin-induced congestive heart failure.
Ann Intern Med; 91:710.

- **Von Hoff, DD, Rozencweig, M, Layard, M, et al.(1977):**
Daunomycin-induced cardiotoxicity in children and adults.
A review of 110 cases. Am J Med; 62:220.

- **Warren, SE, McKay, RG, Aroesty, JM, et al.(2002):**
Comparison of methods for determining absolute left ventricular volumes from radionuclide ventriculography.
Am J Physiol Imaging; 2:24.

- **Wexler, LH, Andrich, MP, Venzon, D, et al.(1996):**
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
J Clin Oncol; 14:362.

- **Weyman AE (2007):**
The year in echocardiography. An overview of the developments in echocardiography.
Am J Coll Cardiol 49:1212-1219.

- **Williams, KA, Taillon, LA.(1996):**

Left ventricular function in patients with coronary artery disease assessed by gated tomographic myocardial perfusion images. Comparison with assessment by contrast ventriculography and first-pass radionuclide angiography.
J Am Coll Cardiol; 27:173

- **Yeh, ET, Tong, AT, Lenihan, DJ, et al.(2004):**

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.
Circulation; 109:3122.

- **Yildirim, Y, Gultekin, E, Avci, ME, et al.(2008):**

Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer.
Int J Gynecol Cancer; 18:223.

- **Yong, Y, Wu, D, Fernandes, V, et al.(2002):**

Diagnostic accuracy and cost-effectiveness of contrast echocardiography on evaluation of cardiac function in technically very difficult patients in the intensive care unit.
Am J Cardiol; 89:711.

- **Zaret, BL, Wackers, FJ, Terrin, ML, et al.(1995):**

Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute MI: Results of thrombolysis in myocardial infarction (TIMI) Phase II Study. The TIMI Study Group.
J Am Coll Cardiol; 26:73.